The Molecular Biology Core Facility at CWRU has operated for almost 8 years, providing state-of-the-art scientific capabilities to the research community, especially where expensive instrumentation or unique technical capabilities are required. To this end, the Core Facility has acquired a variety of instruments, the heart of which is 2 DNA synthesizers and a protein microsequencer. Based upon current limitations within the CWRU community, it is proposed that the Core Facility be expanded to provide the following: peptide synthesis, DNA sequencing, and large scale (up to 20 liters) fermentation of mammalian and microbial cultures. The necessity for these capabilities research projects as well as new investigators added to the CWRU faculty in the last two years. Funds are requested for the purchase of (i), a DNA sequencer (ii), a large scale fermenter and centrifuge for microbial fermentation and (iii), mammalian fermentation equipment. In addition, funds are requested to replace an eight year old DNA synthesizer. This replacement will allow for larger numbers of oligonucleotides to be prepared and will greatly upgrade both the reliability and capability of the synthesis of DNA oligonucleotides with or without non-standard nucleotides. In addition to instrumentation, funds are requested for partial support of three research technicians, associated with DNA sequencing, peptide synthesis (a peptide synthesizer exists in the Core Facility and is available to the CWRU community, however, past demand had not been sufficient to warrant hiring a technician for this effort) and bio-fermentation. These individuals will be associated with the unique demands of just a single instrument which will involve both reparative and analytical functions. Salary support of technical staff will gradually decrease throughout the funding period, and will be recovered by user fee. Calculation of user fees reflects the cost of supplies, salary support and annual maintenance contracts (due to the complex electronics of the instrument within the Core Facility, all are routinely covered by extended maintenance agreements with the manufacturer, although in some instances the appropriate individual may do trouble-shooting when a problem arises). The Core Facility has been operational for the last eight years and is familiar with the establishment of users fees. It has been the practice of the Core Facility to recover costs only as they are associated with each service and to not have any service supported by another.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
1P30AI036219-01
Application #
3747633
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786

Showing the most recent 10 out of 539 publications